Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care
Penson A, Camacho N, Zheng Y, Varghese A, Al-Ahmadie H, Razavi P, Chandarlapaty S, Vallejo C, Vakiani E, Gilewski T, Rosenberg J, Shady M, Tsui D, Reales D, Abeshouse A, Syed A, Zehir A, Schultz N, Ladanyi M, Solit D, Klimstra D, Hyman D, Taylor B, Berger M. Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncology 2020, 6: 84-91. PMID: 31725847, PMCID: PMC6865333, DOI: 10.1001/jamaoncol.2019.3985.Peer-Reviewed Original ResearchConceptsTumor typesTissue of originGenomic analysis of plasma cell-free DNADNA sequence dataPlasma cell-free DNAClinical DNA sequencingOncology practiceAnalysis of plasma cell-free DNAMetastatic breast cancerTumor biological characteristicsCohort of patientsTargeted tumor sequencingCell-free DNASequence dataSite of originGenomic analysisDNA sequencesClinical responseHistologic reviewTumor originMutant geneTherapeutic sensitivityBreast cancerMolecular alterationsDiverse clinical settings
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply